Retrotope, Inc. is a drug development company advancing the idea that polyunsaturated fatty acids (PUFA) drugs fortified with heavy isotopes (reinforced lipids) protect living cells by making bonds within the delicate molecules inside and around cells harder to break. This makes the cells less prone to damage caused by reactive oxygen species (ROS), one of the principal causes of ageing and age-associated diseases.[2] Founded in 2006 by entrepreneurs and scientists with seed funding from private investors, Retrotope is developing a non-antioxidant approach to preventing lipid peroxidation, a detrimental factor in mitochondrial, neuronal, and retinal diseases.[3] The company employs the virtual business model[4] and works in scientific collaboration with more than 80 research groups in universities worldwide.[5]
^"Lifeboat Foundation Bios: Dr. Mikhail S. Shchepinov". lifeboat.com.
^Demidov VV (August 2020). "Site-specifically deuterated essential lipids as new drugs against neuronal, retinal and vascular degeneration". Drug Discovery Today. 25 (8): 1469–1476. doi:10.1016/j.drudis.2020.03.014. PMID 32247036. S2CID 214794450.
^"Retrotope Inc.: Private Company Information". bloomberg.com. Archived from the original on 2018-05-11.
^Keshavan M (22 August 2014). "Fat-based Parkinson's drug headed to clinical trial with $6.5M in angel money". MedCity News.
Retrotope, Inc. is a drug development company advancing the idea that polyunsaturated fatty acids (PUFA) drugs fortified with heavy isotopes (reinforced...
a director of Network Associates from 1997 to 1998, and chairman of Retrotope until 2020. In 2002, Saal was chosen by the United States Department of...
cells. Deuterated ethyl ester of linoleic acid (RT001), developed by Retrotope, is in a compassionate use trial in infantile neuroaxonal dystrophy and...
laboratory at Boston University. He is also a co-founder and Director of Retrotope, a US-based company using heavier isotopes of carbon (13C) and hydrogen...
conditions. Concert was acquired by Sun Pharma in March 2023. The company Retrotope discovered and has been developing a deuterated fatty acid RT001 as a...
comparator-controlled Phase I/II clinical trial for Friedreich's ataxia, sponsored by Retrotope and Friedreich's Ataxia Research Alliance, was conducted to determine...
JSTOR 3350258. PMID 7776947. "US FDA Grants Orphan Drug Designation for Retrotope's RT001 in the Treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration"...
D2-linoleic acid ethyl ester (RT001) for Friedreich's ataxia, sponsored by Retrotope and Friedreich's Ataxia Research Alliance, was conducted to determine...
INC, as well as a board member of the American pharmaceutical company Retrotope, specializing in biotechnology. Artemev is interested in projects related...
biomolecules taken up by the body will be more resistant to ROS. The company Retrotope pioneered the development a source of deuterated omega-6 fatty acid di-deuterated...
Global Information